Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero

Status Completed

Clinical Trial Summary

This prospective cohort study will determine the natural history of fetal exposure to Zika virus (ZIKV) and its effects on the fetus and newborn with emphasis on neurodevelopment outcome. Exposure of the fetus will be determined by maternal symptomatology, RT-PCR ZIKV (blood and urine) and serologic test specific for ZIKV. Neonates will be classified according to trimester of infection and as exposed and unexposed to ZIKV.

Clinical Trial Description

Infection with Zika Virus (ZIKV) is an emerging disease in South America and a serious public health problem due to a high prevalence of one of the vectors that transmit the virus, Aedes Aegypti, and the severe and sometimes fatal complications that can be generated in the fetus of women infected by the virus during their pregnancy. Retrospective studies have shown an association with microcephaly, cerebral calcifications, dysgenesis of the corpus callosum, and other anomalies of the central nervous system (CNS). The high risk of neurodevelopmental impairment in the exposed newborn is a major concern. The epidemiologic and neurobiological evidence supporting the link between infection of pregnant women, trimester of infection, and the development of such anomalies in the fetus is growing to the extent that the Center for Disease Control has officially made a statement supporting this association. Although the dimension of the public health impact is still unknown, limited prospective data makes counseling of pregnant women difficult, especially when they are considering termination of pregnancy. Given that evidence supporting the neurotropic quality of ZIKV and the potential variations of the effect the virus may have on the developing fetal brain according to the gestational age of infection, we have designed a prospective cohort study to determine whether exposure of the fetus to ZIKV in symptomatic mothers results in fetal CNS anomalies and/or impaired neurodevelopmental outcome of the newborn. As a secondary aim we will determine the effect gestational age has on severity of CNS anomalies and neurodevelopmental outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02943304
Study type	Observational
Source	Universidad Industrial de Santander
Contact
Status	Completed
Phase
Start date	May 1, 2016
Completion date	December 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02791321` - Fragility Assessment in Adults With ADHD and Mental Retardation	N/A
Recruiting	`NCT01908400` - Safety and Efficacy of BMMNCin Patients With Mental Retardation	Phase 1/Phase 2
Withdrawn	`NCT02245724` - Stem Cell Therapy in Mental Retardation	Phase 1
Completed	`NCT00156221` - MR Scanning of Very Young Children With Severe Developmental Disorders	N/A
Recruiting	`NCT00491478` - Repetitive Behavior Disorders in People With Severe Mental Retardation	Phase 3
Terminated	`NCT02797418` - "Cognitus & Moi": a New Cognitive Remediation Tool	N/A
Completed	`NCT00758108` - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Completed	`NCT01430845` - Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay
Not yet recruiting	`NCT02214745` - Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community	N/A
Active, not recruiting	`NCT00552526` - Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy	Phase 4
Completed	`NCT00491894` - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions	Phase 3
Completed	`NCT01291238` - School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability.	N/A
Completed	`NCT01456910` - Resistance Training Program, Labor Inclusion, Intellectual Disability	N/A
Completed	`NCT00065273` - Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay	Phase 3
Active, not recruiting	`NCT00065936` - Self-Injury: Diagnosis and Treatment	Phase 3
Completed	`NCT00506259` - Treatment Strategies for Children With Smith-Magenis Syndrome	Phase 1
Not yet recruiting	`NCT05442229` - A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years
Active, not recruiting	`NCT06370793` - Ningbo Severe Mental Disorders Cohort
Completed	`NCT01517048` - Brain-Derived Neurotrophic Factor in Obesity and Brain Function
Completed	`NCT03847753` - Exploring the Comorbidity Between Mental Disorders and General Medical Conditions

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero — ZENI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms